RxDoctor Payments Data

Asmitha Sathiyakumar, MD

Pain Medicine · Fort Payne, ALNPI 1518223718

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 40.7% of the total.

$2,246in general payments, 2019–2025

Across 159 payments — averaging $14.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$915
  • Boston Scientific$330
  • Collegium Pharmaceutical, Inc.$210
  • Medtronic$195
  • AbbVie$122
  • Abbott$66
  • plus $408 from 15 others

What the payments were for

  • Food & beverage$2,246100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,246 in reported general payments places this provider in the 55th percentile of 77 pain medicine providers in Alabama.

See all pain medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$376,592
Medicare patients
451
Services billed
4,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl124$116,704
RelistorMethylnaltrexone Bromide29$56,966
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,344$30,906
Buprenorphine105$28,676
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen702$20,807
Gabapentin837$8,448
Diclofenac Sodium99$5,950
MovantikNaloxegol Oxalate14$5,532
Naloxone Hcl72$5,427
Lidocaine64$4,937
Pregabalin424$4,571
Oxycodone Hcl305$4,425
Tizanidine Hcl348$3,394
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl20$2,022
Baclofen133$1,644

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$210$116,704124 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$915$56,96629 claims
Redhill Biopharma Inc.Movantik$47$5,53214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 77 pain medicine providers in Alabama.

Other pain medicine in Fort Payne

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →